Press Releases
Press Releases
More Press Releases
View Older Stories View Newer Stories-
Hagerty Reports Second Quarter 2024 Results
-
ModernFi Announces the Formation and Funding of ModernFi CUSO to Support Credit Union Deposit and Member Growth
-
Galvanize Therapeutics Completes Enrollment in Clinical Trial Evaluating Aliya® Pulsed Electric Field (PEF) System for Late-Stage Non-Small Cell Lung Cancer and Metastasis to the Lung
-
Carbon Accountable Unveils CA SB 253: A Regulations Roadmap, Demonstrates Feasibility of 2026 Implementation
-
25 Snack Food Suppliers Queue Up for ReposiTrak’s Rapidly Expanding Food Traceability Network
-
New Jersey Resources Reports Fiscal 2024 Third-Quarter Results
-
Main Street Announces Fourth Quarter 2024 Regular Monthly Dividends and Supplemental Dividend Payable in September 2024
-
Sherritt Appoints Shelley Brown to its Board of Directors
-
Flashpoint Unveils New Investigations Management, Intelligence Requirements Mapping, and Geolocation Protection Capabilities at Black Hat USA 2024
-
NeuroMetrix Reports Q2 2024 Business Highlights and Update on Review of Strategic Options
-
Compugen Reports Second Quarter 2024 Results
-
1stDibs Reports Second Quarter 2024 Financial Results
-
Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2024
-
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2024 SECOND QUARTER FINANCIAL STATEMENTS AND CONFERENCE CALL INFORMATION
-
Arbe Announces Q2 2024 Financial Results
-
American Shared Hospital Services Announces Start of Patient Treatments at its Radiation Therapy Facility, A.B. Radiocirugía y Radioterapia de Puebla, in Puebla, Mexico
-
Samsung Biologics joins the Pharmaceutical Supply Chain Initiative as Supplier Partner
-
The Cannabist Company Celebrates Start of Adult-Use Retail Sales and Wholesale Distribution in Ohio
-
Murf Electric Bikes Unveils Redesigned Izzy Step-Thru
-
Augmedix to Announce Second Quarter 2024 Financial Results on August 12, 2024
-
Neumora Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
-
AdaptHealth Corp. Announces Second Quarter 2024 Results
-
Fuller Theological Seminary Announces the Launch of "The New Testament in Color"
-
Hemlo Explorers Enters Share Purchase Agreements for the Acquisition of Rocky Shore Metals and its Gold Anchor Project
-
Angel Oak Mortgage REIT, Inc. Reports Second Quarter 2024 Financial Results
-
Luca Mining Engages Mining Contractor for Campo Morado
-
MindMed to Host Conference Call and Webcast to Discuss Second Quarter 2024 Financial Results and Provide Business Update
-
Apple Tree Partners Launches Red Queen Therapeutics to Bring Potentially Lifesaving Treatments to People at Greatest Risk from Viral Infections
-
Bentley Systems Announces Second Quarter 2024 Results
-
NexGold Mining and Wabigoon Lake Ojibway Nation Sign New Relationship Agreement for Goliath Gold Complex
-
Accounting & Business Advisory Leader Clark Schaefer Hackett Chooses AI Networking with Nile
-
BMO Launches Enhanced Premium Rewards Credit Card with Mastercard to Help Customers Make Real Financial Progress
-
Celebrated New Children's Book "A Tall Tale: How the Ostriches Got Their Long Necks and Long Legs" Promotes Lessons of Compromise and Collaboration
-
Duke Energy reports second-quarter 2024 financial results
-
HAMILTON LANE INCORPORATED REPORTS FIRST QUARTER FISCAL 2025 RESULTS, WITH MANAGEMENT & ADVISORY FEES GROWING BY 33% AND ASSETS UNDER MANAGEMENT GROWING BY 11% YEAR-OVER-YEAR
-
Broadridge Reports Fourth Quarter and Fiscal 2024 Results
-
Builders FirstSource Reports Second Quarter 2024 Results
-
Davidson Technologies and D-Wave Partnership Receives Strong Support from Local and Federal Lawmakers for Bringing Advanced Quantum Computing to Alabama and National Defense Efforts
-
SEED Therapeutics (SEED) Enters into Strategic Research Collaboration with Eisai Co., Ltd. to Discover and Develop Novel Molecular Glue Degraders for Neurodegeneration and Oncology Indications
-
Elevation Oncology Announces Promising Initial Data from Phase 1 Clinical Trial Evaluating EO-3021 in Patients with Advanced Unresectable or Metastatic Solid Tumors Likely to Express Claudin 18.2
-
Origin Materials Unveils Engineering and Design Innovation in Its Manufacturing of Tethered PET Beverage Caps
-
Seres Therapeutics to Announce Second Quarter 2024 Financial Results and Business Update on August 13, 2024
-
Creative Realities Elevates Game Day with Innovative Digital Signage in Sports & Entertainment Venues
-
Moody’s Corporation to Present at the Oppenheimer Annual Technology, Internet and Communications Conference on August 12, 2024
-
Meharry Medical College Receives $175 Million from Bloomberg Philanthropies
-
National Renewable Solutions Announces Promotions to Expand its Executive Leadership
-
Chimerix to Report Second Quarter 2024 Financial Results and Provide an Operational Update on August 13, 2024
-
Builders FirstSource Authorizes $1 Billion Share Repurchase Plan
-
Central Pacific Bank Selects ARGO’s Suite of Retail Banking Software
-
Mueller Industries, Inc. Announces Acquisition of Elkhart Products Corporation
